Clinical trials

Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer
Stephanie Lheureux, Daniela E Matei, Panagiotis A Konstantinopoulos, Ben X Wang, Ramy Gadalla, Matthew S Block, Andrea Jewell, Stephanie L Gaillard, Michael McHale, Carolyn McCourt, Sarah Temkin, Eugenia Girda, Floor J Backes, Theresa L Werner, Linda Duska, Siobhan Kehoe, Ilaria Colombo, Lisa Wang, Xuan Li, Rachel Wildman, Shirin Soleimani, Scott Lien, John Wright, Trevor Pugh, Pamela S Ohashi, David G Brooks, Gini F Fleming

Journal for ImmunoTherapy of Cancer Mar 2022, 10 (3) e004233; DOI: 10.1136/jitc-2021-004233
Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer
Carey K Anders, Mark G Woodcock, Amanda E D Van Swearingen, Dominic T Moore, Maria J Sambade, Sonia Laurie, Alexander Robeson, Oleg Kolupaev, Luz A Cuaboy, Amy L Garrett, Karen McKinnon, Kristen Cowens, Dante Bortone, Benjamin C Calhoun, Alec D Wilkinson, Lisa Carey, Trevor Jolly, Hyman Muss, Katherine Reeder-Hayes, Rebecca Kaltman, Rachel Jankowitz, Vinay Gudena, Oludamilola Olajide, Charles Perou, E Claire Dees, Benjamin G Vincent, Jonathan S Serody

Journal for ImmunoTherapy of Cancer Feb 2022, 10 (2) e003427; DOI: 10.1136/jitc-2021-003427
Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)
Takashi Seto, Kaname Nosaki, Mototsugu Shimokawa, Ryo Toyozawa, Shunichi Sugawara, Hidetoshi Hayashi, Haruyasu Murakami, Terufumi Kato, Seiji Niho, Hideo Saka, Masahide Oki, Hiroshige Yoshioka, Isamu Okamoto, Haruko Daga, Koichi Azuma, Hiroshi Tanaka, Kazumi Nishino, Rie Tohnai, Nobuyuki Yamamoto, Kazuhiko Nakagawa

Journal for ImmunoTherapy of Cancer Feb 2022, 10 (2) e004025; DOI: 10.1136/jitc-2021-004025
Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study
Lingfang Xia, Jin Peng, Ge Lou, Mei Pan, Qi Zhou, Wenjing Hu, Huirong Shi, Li Wang, Yunong Gao, Jianqing Zhu, Yu Zhang, Rong Sun, Xianfeng Zhou, Quanren Wang, Xiaohua Wu

Journal for ImmunoTherapy of Cancer Jan 2022, 10 (1) e003831; DOI: 10.1136/jitc-2021-003831
Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial
Lukas Rob, David Cibula, Pawel Knapp, Peter Mallmann, Jaroslav Klat, Lubos Minar, Pavel Bartos, Josef Chovanec, Petr Valha, Marek Pluta, Zdenek Novotny, Jiri Spacek, Bohuslav Melichar, Dariusz Kieszko, Jitka Fucikova, Tereza Hrnciarova, Roman Pawel Korolkiewicz, Marek Hraska, Jirina Bartunkova, Radek Spisek

Journal for ImmunoTherapy of Cancer Jan 2022, 10 (1) e003190; DOI: 10.1136/jitc-2021-003190
Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival
Manish A Shah, David Cunningham, Jean-Philippe Metges, Eric Van Cutsem, Zev Wainberg, Emon Elboudwarej, Kai-Wen Lin, Scott Turner, Marianna Zavodovskaya, David Inzunza, Jinfeng Liu, Scott D Patterson, Jingzhu Zhou, Jing He, Dung Thai, Pankaj Bhargava, Carrie Baker Brachmann, Daniel V T Cantenacci

Journal for ImmunoTherapy of Cancer Dec 2021, 9 (12) e003580; DOI: 10.1136/jitc-2021-003580
Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study
Sara Lonardi, Alessandra Anna Prete, Federica Morano, Marco Messina, Vincenzo Formica, Domenico Cristiano Corsi, Corrado Orciuolo, Giovanni Luca Frassineti, Maria Giulia Zampino, Mariaelena Casagrande, Gianluca Masi, Monica Ronzoni, Mario Scartozzi, Angela Buonadonna, Stefania Mosconi, Margherita Ratti, Andrea Sartore-Bianchi, Emiliano Tamburini, Michele Prisciandaro, Francesca Bergamo, Massimiliano Spada, Salvatore Corallo, Valentina Vettore, Fotios Loupakis, Matteo Fassan, Paola Del Bianco, Vittorina Zagonel, Filippo Pietrantonio

Journal for ImmunoTherapy of Cancer Nov 2021, 9 (11) e002996; DOI: 10.1136/jitc-2021-002996
Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067
Meredith M Regan, Charlene M Mantia, Lillian Werner, Ahmad A Tarhini, James Larkin, F Stephen Hodi, Jedd Wolchok, Michael A Postow, Brian Stwalley, Andriy Moshyk, Corey Ritchings, Sandra Re, Wim van Dijck, David F McDermott, Michael B Atkins

Journal for ImmunoTherapy of Cancer Nov 2021, 9 (11) e003743; DOI: 10.1136/jitc-2021-003743
Toripalimab plus intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma: an open-label single-arm, phase II trial
Yijun Hua, Rui You, Zhiqiang Wang, Peiyu Huang, Mei Lin, Yanfeng Ouyang, Yulong Xie, Xiong Zou, Youping Liu, Chongyang Duan, Yonglong Liu, Chenmei Gu, Rongzeng Liu, Qi Yang, Rou Jiang, Mengxia Zhang, Xi Ding, Siyuan Chen, Chao Lin, Rui Sun, Mingyuan Chen

Journal for ImmunoTherapy of Cancer Nov 2021, 9 (11) e003290; DOI: 10.1136/jitc-2021-003290
Letter to the editor from Pant et al
Shubham Pant, Justin T Moyers, Aung Naing

Journal for ImmunoTherapy of Cancer Nov 2021, 9 (11) e003991; DOI: 10.1136/jitc-2021-003991

Main menu

Clinical trials

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Clinical trials

Pages